A Phase 1/2 interventional study of Zalifrelimab in Advanced Solid Cancers and Advanced Solid Cancers Refractory to PD-1 and PD-L1 Therapies, sponsored by Agenus Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Agenus Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, Phase 1/2, multicenter study to evaluate the safety, pharmacokinetics, and pharmacodynamics of an anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) human monoclonal antibody (zalifrelimab) in participants with advanced or refractory cancer and in participants who have progressed during treatment with a programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitor as their most recent therapy.
The phase 1 portion of the study has been completed; it enrolled adult participants with refractory, advanced cancer in a 3+3 dose escalation cohort.
The phase 2 portion consisted of 51 participants who progressed during treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug).
Agenus Inc. is the lead sponsor of 31 studies on the registry; 2 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 3 (27%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Primary or secondary immunodeficiency, including disease, disease (including autoimmune endocrinopathies), or usage of immunosuppressive medications.
Note: Participants with diabetes type 1, vitiligo, psoriasis, hypo-, or hyperthyroid disease not requiring immunosuppressive treatment are eligible. Participants with Type 2 diabetes mellitus are allowed.
Participants with a known history of 1 and 2, human T lymphotropic virus 1.
Participants in Phase 2 with HCC: Participants with active infection who are receiving effective antiviral therapy are permitted. Participants with active infection are allowed (antiviral therapy not required).
Administration of anticancer medications or drugs within the following intervals before the first administration of study drug: a. ≤14 days for chemotherapy, targeted small molecule therapy, or radiation therapy. Participants must also not have had radiation pneumonitis as a result of treatment and cannot participate in the study if they are on chronic corticosteroids for radiation pneumonitis. A 1-week is permitted for palliative radiation to non-central nervous system (CNS) disease, with medical monitor approval.
Note: Bisphosphonates and denosumab are permitted medications. b. ≤14 days for prior immunotherapy. Participants in the dose escalation cohorts are excluded if they have received prior , costimulatory agonists, or immune modulating therapy except as described below. Once a dose level is determined to be safe by the safety review committee, participants will be allowed to enroll in dose-level expansion cohorts if they have received other non-CTLA-4 targeting immunotherapies.
c. Participants enrolling in Phase 2 must have cancer that has progressed after prior treatment with an approved or investigational PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug). The minimum requirement of 2 weeks (14 days) from prior anti-PD-1/PD-L1 therapy is to allow resolution of any lower-grade (≤2) adverse events observed with the therapy. If the investigator feels the participant has tolerated prior anti-PD-1/PD-L1 therapy well, then treatment with study agent may begin sooner.
d. ≤7 days for prior corticosteroid treatment, with the following exceptions:
Use of physiologic corticosteroid replacement therapy may be approved after consultation with the medical monitor. e. ≤21 days for prior monoclonal antibody used for anticancer therapy, with the exception of denosumab. This does not apply to participants being enrolled in Phase 2, who have received a PD-1/PD-L1 inhibitor as their most recent therapy (2-6 weeks prior to first dose of study drug; see above).
f. ≤7 days for immunosuppressive-based treatment for any reason, with the exceptions noted above for prior corticosteroid treatment (exclusion criterion d).
g. ≤21 days or 5 half-lives before first dose of study treatment for all other investigational study drugs or devices. For investigational agents with long half- lives (for example, >5 days), enrollment before the fifth half-life requires medical monitor approval.
h. For participants in Phase 2 with HCC \<6 weeks for prior locoregional therapy to the liver, for example, transcatheter chemoembolization, radiation, surgery, or radioembolization.
Has not recovered to grade ≤1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy.
Note: Participants with grade ≤2 neuropathy and alopecia are an exception and may enroll.
For participants in Phase 2 with HCC, the following exclusions also apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received zalifrelimab intravenously.
Drug: Zalifrelimab
An anti-CTLA-4 monoclonal antibody.
Also known as: AGEN1884
Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab
A DLT was defined as a Grade ≥3 adverse drug reaction (ADR), according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5, occurring in the DLT evaluation period (28 days after the initial administration of zalifrelimab). An ADR was defined as all noxious and unintended responses to a medicinal product, related to any dose.
Time frame: Up to 28 days
Phase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse Events
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. A treatment-related AE was one in which a causal relationship between the medicinal product and the AE was at least a reasonable possibility and could not be ruled out. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Up to 6 years
Phase 1: Maximum Drug Concentration (Cmax) of Zalifrelimab
Blood samples were collected at designated timepoints to characterize Cmax of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as micrograms/milliliter (ug/mL).
Time frame: Day 1 of Cycle 1 (21 days/cycle)
Phase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of Zalifrelimab
Blood samples were collected at designated timepoints to characterize AUC0-21d of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as hour times ug/mL (hour\*ug/mL).
Time frame: Day 1 of Cycle 1 (21 days/cycle)
Phase 1 and Phase 2: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by radiographic disease assessments per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). BOR was defined as the best response recorded from the start of treatment until disease progression/recurrence; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time frame: Up to 6 years
Phase 1 and Phase 2: Disease Control Rate (DCR)
DCR was defined as the percentage of participants who had a confirmed response (CR or PR) or stable disease (SD) without progressive disease (PD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
Time frame: Up to 6 years
Phase 1 and Phase 2: Duration of Response (DOR)
DOR was defined as the interval from which the date measurement criteria were met for CR or PR (whichever was first recorded) until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause, if occurring sooner than progression.
Time frame: Up to 6 years
Phase 1: Progression-free Survival (PFS)
PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.
Time frame: Up to 6 years
Phase 2: PFS
PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.
Time frame: Up to 6 years
Phase 1: Overall Survival (OS)
OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.
Time frame: Up to 6 years
Phase 2: OS
OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.
Time frame: Up to 6 years
| Milestone | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| Started | 5 | 3 | 10 | 15 | 5 | 0 |
| Received at least 1 dose of study drug | 5 | 3 | 10 | 15 | 5 | 0 |
| Completed | 1 | 0 | 0 | 1 | 1 | 0 |
| Not completed | 4 | 3 | 10 | 14 | 4 | 0 |
| Withdrew: Death | 2 | 1 | 6 | 6 | 3 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 4 | 8 | 1 | 0 |
| Milestone | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 51 |
| Received at least 1 dose of study drug | 0 | 0 | 0 | 0 | 0 | 51 |
| Completed | 0 | 0 | 0 | 0 | 0 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 43 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 26 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 13 |
| Withdrew: Administrative study closure | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participant transferred to another site | 0 | 0 | 0 | 0 | 0 | 1 |
A DLT was defined as a Grade ≥3 adverse drug reaction (ADR), according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5, occurring in the DLT evaluation period (28 days after the initial administration of zalifrelimab). An ADR was defined as all noxious and unintended responses to a medicinal product, related to any dose.
| Participants | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs) of Zalifrelimab | 0 | 0 | 0 | 0 | 0 |
An adverse event (AE) was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily have a causal relationship with this treatment. A treatment-related AE was one in which a causal relationship between the medicinal product and the AE was at least a reasonable possibility and could not be ruled out. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| Phase 1 and Phase 2: Number of Participants Experiencing Any Treatment-related Adverse Events | 3 | 2 | 6 | 12 | 4 | 31 |
Blood samples were collected at designated timepoints to characterize Cmax of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as micrograms/milliliter (ug/mL).
| ug/mL | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Maximum Drug Concentration (Cmax) of Zalifrelimab | 1.95 ± 0.30946 | 7.15 ± 1.3635 | 23.1 ± 1.2891 | 63.5 ± 9.4314 | 120 ± 18.075 |
Blood samples were collected at designated timepoints to characterize AUC0-21d of serum zalifrelimab following IV infusion in participants with metastatic or locally advanced solid tumors. Data reported as hour times ug/mL (hour\*ug/mL).
| hour*ug/mL | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Area Under the Drug Concentration-time Curve From 0 to 21 Days (AUC0-21d) of Zalifrelimab | 317 ± 51.897 | 1522 ± 246.42 | 3915 ± 964.89 | 11390 ± 964.89 | 18803 ± 2370.77 |
ORR was defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) as determined by radiographic disease assessments per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). BOR was defined as the best response recorded from the start of treatment until disease progression/recurrence; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters. CR was defined as disappearance of all target lesions, and PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
| percentage of participants | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| Phase 1 and Phase 2: Objective Response Rate (ORR) | 20.0 (0.5 to 71.6) | 0 (0.0 to 70.8) | 0 (0.0 to 30.9) | 0 (0.0 to 21.8) | 0 (0.0 to 52.2) | 5.9 (2.0 to 15.9) |
DCR was defined as the percentage of participants who had a confirmed response (CR or PR) or stable disease (SD) without progressive disease (PD). SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this included the baseline sum if that is the smallest on study).
| percentage of participants | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| Phase 1 and Phase 2: Disease Control Rate (DCR) | 20.0 (0.5 to 71.6) | 33.3 (0.8 to 90.6) | 0 (0.0 to 30.9) | 6.7 (0.2 to 32.0) | 0 (0.0 to 52.2) | 37.3 (25.3 to 51.0) |
DOR was defined as the interval from which the date measurement criteria were met for CR or PR (whichever was first recorded) until the earliest date of disease progression, as determined by investigator assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause, if occurring sooner than progression.
| weeks | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| Phase 1 and Phase 2: Duration of Response (DOR) | NA (NA to NA) | — | — | — | — | NA (NA to NA) |
PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.
| weeks | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Progression-free Survival (PFS) | NA (3.143 to NA) | 11.000 (4.429 to NA) | 10.429 (5.286 to 12.429) | 11.143 (7.143 to 16.286) | 5.714 (2.571 to NA) |
PFS was defined as the interval from the date of first dose of investigational agent until the earliest date of PD, as determined by independent endpoint review committee assessment of objective radiographic disease assessments per RECIST v1.1, or death due to any cause if occurring sooner than progression.
| months | Phase 2: Zalifrelimab |
|---|---|
| Phase 2: PFS | 2.0 (1.4 to 2.9) |
OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.
| weeks | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 |
|---|---|---|---|---|---|
| Phase 1: Overall Survival (OS) | NA (17.429 to NA) | 71.143 (NA to NA) | 20.429 (2.000 to 49.857) | 70.571 (9.857 to NA) | 15.000 (4.857 to NA) |
OS was defined as the interval from the date of first dose of investigational agent until the date of death. For participants who did not die, OS was censored at last contact date.
| months | Phase 2: Zalifrelimab |
|---|---|
| Phase 2: OS | 16.8 (5.7 to 25.6) |
Collected over From Day 1 to the end of study (6 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Zalifrelimab Dose 1 | 2/5 (40%) | 2/5 (40%) | 5/5 (100%) |
| Phase 1: Zalifrelimab Dose 2 | 1/3 (33.3%) | 2/3 (66.7%) | 3/3 (100%) |
| Phase 1: Zalifrelimab Dose 3 | 6/10 (60%) | 5/10 (50%) | 10/10 (100%) |
| Phase 1: Zalifrelimab Dose 4 | 6/15 (40%) | 9/15 (60%) | 15/15 (100%) |
| Phase 1: Zalifrelimab Dose 5 | 3/5 (60%) | 3/5 (60%) | 5/5 (100%) |
| Phase 2: Zalifrelimab | 26/51 (51%) | 23/51 (45.1%) | 48/51 (94.1%) |
| Event | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/5 | 1/3 | 0/10 | 0/15 | 0/5 | 0/51 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/5 | 1/3 | 0/10 | 1/15 | 0/5 | 2/51 |
| Abdominal painGastrointestinal disorders | 0/5 | 0/3 | 1/10 | 0/15 | 1/5 | 1/51 |
| Oesophagael obstructionGastrointestinal disorders | 0/5 | 0/3 | 0/10 | 0/15 | 1/5 | 0/51 |
| VomitingGastrointestinal disorders | 0/5 | 0/3 | 0/10 | 0/15 | 1/5 | 0/51 |
| SepsisInfections and infestations | 0/5 | 0/3 | 2/10 | 0/15 | 0/5 | 1/51 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/5 | 0/3 | 0/10 | 0/15 | 1/5 | 0/51 |
| AstheniaGeneral disorders | 1/5 | 0/3 | 0/10 | 0/15 | 0/5 | 0/51 |
| General physical health deteriorationGeneral disorders | 0/5 | 0/3 | 0/10 | 0/15 | 1/5 | 0/51 |
| HyperbilirubinaemiaHepatobiliary disorders | 1/5 | 0/3 | 0/10 | 0/15 | 0/5 | 0/51 |
| Event | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab |
|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 0/5 | 1/3 | 5/10 | 9/15 | 4/5 | 17/51 |
| DiarrhoeaGastrointestinal disorders | 1/5 | 2/3 | 2/10 | 7/15 | 2/5 | 13/51 |
| VomitingGastrointestinal disorders | 3/5 | 2/3 | 4/10 | 6/15 | 1/5 | 9/51 |
| DehydrationMetabolism and nutrition disorders | 0/5 | 2/3 | 2/10 | 3/15 | 0/5 | 2/51 |
| NauseaGastrointestinal disorders | 1/5 | 1/3 | 4/10 | 5/15 | 3/5 | 14/51 |
| ConstipationGastrointestinal disorders | 1/5 | 1/3 | 4/10 | 5/15 | 3/5 | 11/51 |
| Abdominal painGastrointestinal disorders | 3/5 | 0/3 | 1/10 | 3/15 | 1/5 | 8/51 |
| Chest painGeneral disorders | 2/5 | 0/3 | 0/10 | 1/15 | 0/5 | 0/51 |
| Non-cardiac chest painGeneral disorders | 0/5 | 0/3 | 0/10 | 0/15 | 2/5 | 0/51 |
| Blood creatinine increasedInvestigations | 0/5 | 1/3 | 2/10 | 6/15 | 1/5 | 5/51 |
Safety Analysis Set: all participants who received at least 1 dose of zalifrelimab.
| Age, Categorical(Participants) | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 5 | 2 | 6 | 7 | 5 | 30 | 55 |
| >=65 years | 0 | 1 | 4 | 8 | 0 | 21 | 34 |
| Sex: Female, Male(Participants) | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab | Total |
|---|---|---|---|---|---|---|---|
| Female | 2 | 2 | 7 | 8 | 3 | 19 | 41 |
| Male | 3 | 1 | 3 | 7 | 2 | 32 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 3 | 4 | 0 | 5 | 14 |
| Not Hispanic or Latino | 4 | 2 | 7 | 11 | 5 | 44 | 73 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Race (NIH/OMB)(Participants) | Phase 1: Zalifrelimab Dose 1 | Phase 1: Zalifrelimab Dose 2 | Phase 1: Zalifrelimab Dose 3 | Phase 1: Zalifrelimab Dose 4 | Phase 1: Zalifrelimab Dose 5 | Phase 2: Zalifrelimab | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 3 | 0 | 5 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 1 | 2 | 0 | 5 | 8 |
| White | 4 | 3 | 9 | 9 | 5 | 39 | 69 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2016 to primary completion in Mar 2022, 71 months.
Results were first posted in Mar 2025, 2 years 11 months after primary completion. A results delay was requested in Feb 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zalifrelimab